Hematoporphyrin monomethyl ether
Based on 3 publication(s) in Google Scholar
Hematoporphyrin monomethyl ether, second generation of porphyrin-related photosensitizer, is characterized by its single form, high yield of singlet oxygen, high selectivity, and low toxicity, which has been widely used in the diagnosis and research of various tumors, including lung cancer, bladder cancer, and nevus flammeus and brain glioma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 95.0%
- CAS 番号: 148471-91-4
- 分子式: C70H80N8O12
- 分子量:1225.43
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Hematoporphyrin monomethyl ether
More
生物活性
製品説明
体外実験
Hematoporphyrin monomethyl ether (HMME) is a novel and promising porphyrin-related photosensitizer for photodynamic therapy (PDT). HMME-PDT can induce cell deaththrough both necrosis and apoptosis in HeLa cells. ROS, such as singlet oxygen and hydroxyl radical, generated in HeLa cells play a decisive role in HMME-PDT-induced cell death[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 148471-91-4
-
性状 Solid
-
分子量 1225.43
-
分子式 C70H80N8O12
-
Color Purple to purplish red
-
SMILES
O=C(CCC(C1=N/2)=C(C)C2=C\C3=C(C(C)OC)C(C)=C(/C=C4N=C(C(C)=C\4C(C)O)/C=C5N/C(C(CCC(O)=O)=C\5C)=C\1)N3)O.O=C(CCC(C6=N/7)=C(C)C7=C\C8=C(C(C)O)C(C)=C(/C=C9N=C(C(C)=C\9C(C)OC)/C=C%10N/C(C(CCC(O)=O)=C\%10C)=C\6)N8)O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy. [Abstract]2025 Dec 16;17(1):272. PMID: 41402324 -
Adv Sci (Weinh)
Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy. [Abstract]2026 May 20:e75770. PMID: 42159453 -
ACS Omega
Carbomer Hydrogel Composed of Cu2O and Hematoporphyrin Monomethyl Ether Promotes the Healing of Infected Wounds. [Abstract]2024 Jan 16;9(4):4974-4985. PMID: 38313474
溶剤 & 溶解度
体外:
DMSO : 62.5 mg/mL (51.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (1.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
ホットトピック
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics Photodynamic Therapy: Past, Current, Future
Photodynamic therapy (PDT) is a light-activated therapeutic modality that combines photosensitizers, oxygen, and specific light wavelengths to generate reactive oxygen species for selective cellular destruction.
2026-06-02
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8160 mL | 4.0802 mL | 8.1604 mL | 20.4010 mL |
| 5 mM | 0.1632 mL | 0.8160 mL | 1.6321 mL | 4.0802 mL | |
| 10 mM | 0.0816 mL | 0.4080 mL | 0.8160 mL | 2.0401 mL | |
| 15 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3601 mL | |
| 20 mM | 0.0408 mL | 0.2040 mL | 0.4080 mL | 1.0201 mL | |
| 25 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8160 mL | |
| 30 mM | 0.0272 mL | 0.1360 mL | 0.2720 mL | 0.6800 mL | |
| 40 mM | 0.0204 mL | 0.1020 mL | 0.2040 mL | 0.5100 mL | |
| 50 mM | 0.0163 mL | 0.0816 mL | 0.1632 mL | 0.4080 mL |
Hematoporphyrin monomethyl ether 関連分類
HY-134990 関連分類
Powered by Bioz